Roche Italia
- Company typePrivate
- Founded1897
- HeadquartersMonza, Lombardy, Italy
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
Roche Italia firmographics
Firmographics- Name
- Roche Italia
- Legal name
- Roche S.p.A.
- Website
- https://roche.it
- Company type
- Private
- Founded year
- 1897
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Roche Italia industry classification
Industry- Product category
- Pharmaceuticals and Diagnostics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industries
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Ophthalmology Pharmaceuticals (HLAIAAAL), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Roche Italia is headquartered
LocationHeadquarters
- HQ city
- Monza, Lombardy
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Roche Italia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Products: Roche Italia develops and commercializes innovative pharmaceutical products across oncology, neurology, rare diseases, infectious diseases, ophthalmology, and cardiovascular diseases. Revenue is generated through product sales to hospitals, clinics, and pharmacies within the Italian National Health Service (SSN) framework.
- Diagnostic Solutions and Products: Roche Diagnostics provides a broad portfolio of diagnostic tests, instruments, and digital solutions to laboratories, hospitals, point-of-care settings, and research institutions. Revenue includes sales of consumables, instruments, software licenses, and related services.
- Diabetes Care Solutions: Roche Diabetes Care provides medical devices including continuous glucose monitoring (CGM) systems, insulin delivery devices, self-monitoring blood glucose meters, and digital health management solutions for diabetes patients.
- Integrated Services and Value-Added Services: Roche provides integrated services alongside therapeutic solutions including home care assistance, telemedicine, and digital health services in collaboration with the Italian National Health Service, contributing to improved care efficacy and efficiency.
- Innovative Reimbursement Models: Roche has introduced innovative reimbursement models to ensure timely and sustainable access to treatments, including extended therapeutic uses and free drug provision programs, in partnership with the Italian healthcare system.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels10 records
Roche Italia product offering
Product offeringCore offering
Roche Italia develops, manufactures, and commercializes pharmaceutical products across oncology, rare diseases, infectious diseases, neuroscience, and ophthalmology, alongside a comprehensive diagnostics portfolio (molecular diagnostics, clinical chemistry, immunochemistry, tissue diagnostics, point-of-care testing, next-generation sequencing, and laboratory automation), and diabetes care solutions including continuous glucose monitoring devices and digital health platforms. The offerings are sold primarily to hospitals, laboratories, and the Italian National Health Service, supported by companion diagnostics and digital platforms.
Product overview
Roche Italia operates as a multinational pharmaceutical and diagnostic company with three main business divisions: Roche S.p.A. (pharmaceuticals), Roche Diagnostics S.p.A. (diagnostic solutions), and Roche Diabetes Care Italy S.p.A. (diabetes management devices and solutions). The pharmaceutical division covers oncology, rare diseases, infectious diseases, neurosciences, and ophthalmology. The diagnostics division provides molecular diagnostics, clinical chemistry, immunochemistry, tissue diagnostics, point of care testing, next generation sequencing, and laboratory automation solutions. Digital platforms supporting these offerings include navify Portal for laboratory services, Modusonline PRO for diabetes digital health, Medora for healthcare professionals, and Roche Healthcare Consulting. Fondazione Roche, established in 2017, supports independent scientific research. The portfolio also includes companion diagnostics and cardiac biomarker tests like NT-proBNP.
Differentiator
Problem solved
Functional benefit
Brands
- Medora: A community platform for healthcare professionals providing the latest innovation updates and information about changing healthcare.
- Modusonline PRO
- Fondazione Roche
Products and services
- Roche Pharmaceuticals (Roche S.p.A.) Pharmaceutical division offering innovative medicines across oncology, rare diseases, infectious diseases, neurosciences, and ophthalmology, focused on personalized healthcare and innovative therapies for Italian hospitals, clinics, and the National Health Service.
- Roche Diagnostics Solutions Diagnostic solutions division providing molecular diagnostics, clinical chemistry, immunochemistry, tissue diagnostics, point-of-care testing, next-generation sequencing, laboratory automation, and digital systems for clinical decision support, serving laboratories and hospitals across Italy.
- Roche Diabetes Care Italy Diabetes care division offering innovative medical devices for glucose monitoring (including continuous glucose monitoring systems), insulin delivery, self-monitoring blood glucose meters, data management solutions, digital health, and population health management for diabetes patients.
- NT-proBNP Cardiac Biomarker Test Cardiac biomarker test for the diagnosis and prognosis of heart failure, available on both laboratory platforms and point-of-care platforms, enabling monitoring in chronic phase at territorial clinics and GP offices for clinicians and laboratory professionals.
- Companion Diagnostics High-value medical tests closely linked to drug development that enable prescription of medicines in patient populations where efficacy and benefit have been demonstrated, particularly in oncology precision medicine, supporting clinicians and the pharmaceutical research pipeline.
- navify Portal Online portal providing access to digital services and solutions designed to simplify and optimize laboratory activities for diagnostic laboratory professionals.
- Modusonline PRO Digital platform for diabetes management and therapy, e-health solutions, digital health evidence sharing, and experience exchange for healthcare professionals and diabetes patients.
- Medora Community platform for healthcare professionals providing the latest medical innovation news, scientific updates, and resources for changing healthcare practice in Italy.
- Roche Healthcare Consulting Organizational consulting services dedicated to healthcare professionals and institutions, supporting diagnostic operations, laboratory organization, and clinical pathway optimization.
Quantifiable outcome
- Over 300 million EUR invested in clinical research in Italy in the last 7 years, contributing to both patient access and NHS sustainability
- +6 more outcomes
Companies that use Roche Italia
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Roche Italia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Roche Italia partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- APMP (Associazioni Pazienti insieme per il diritto alla Medicina Personalizzata in oncologia)coreAPMP brings together 11 patient associations working synergistically so that the right to personalized medicine in oncology is recognized by institutions. Together with Roche's unconditional support, they created the project 'Ogni storia è unica' (Every story is unique) to promote wider access to personalized medicine approaches.
- WALCE (Women Against Lung Cancer in Europe)coreWALCE is a European patient association dedicated to lung cancer awareness. Roche partners with WALCE on the Meet2Talk initiative, a cycle of meetings for lung cancer patients and caregivers, providing information, training, and support.
- IPOP (Insieme per i Pazienti di Oncologia Polmonare)coreIPOP is an Italian patient association for lung cancer patients. Roche partners with IPOP on the Meet2Talk initiative alongside WALCE, providing information and support for NSCLC patients in early-stage disease.
- EpaC ETS (Epatocarcinoma)coreRoche partners with the EpaC patient association on the 'Uniti e Vicini ai Pazienti con Epatocarcinoma' (United and Close to Hepatocellular Carcinoma Patients) initiative, a roadshow promoting multidisciplinary teams and optimal diagnosis and care pathways for HCC patients.
- AIOM (Associazione Italiana di Oncologia Medica)coreAIOM is the Italian Association of Medical Oncology. Roche collaborates with AIOM on multiple oncology initiatives including research funding, clinical guidelines, and awareness campaigns referenced in the 'I numeri del cancro in Italia' report.
- Fujifilm ItaliaminorRoche partnered with Fujifilm Italia on the 'Screening Routine' campaign to support the relaunch of breast cancer screening mammography, which had declined due to the COVID-19 pandemic.
- AIOT (Associazione Italiana di Oncologia Toracica)coreRoche supports AIOT's 'RESPIRIAMO INSIEME' school competition on lung cancer awareness, in partnership with the Ministry of Education, as part of the LungLive program focusing on primary/secondary prevention and precision medicine.
- The Valuable 500coreRoche has made a public commitment to The Valuable 500, an organization whose mission is to leverage the power of companies to promote lasting change for 1.3 billion people with disabilities worldwide. Roche is working on digital accessibility improvements.
- A.N.D.O.S., Europa Donna Italia, F.A.V.O. Donna, IncontraDonna, Salute DonnacoreFive major breast cancer patient associations (A.N.D.O.S., Europa Donna Italia, F.A.V.O. Donna, IncontraDonna, Salute Donna) jointly signed the 'Onconnext' document with Roche, proposing ten concrete measures to renew breast cancer diagnosis and care pathways and strengthen hospital-territory integration.
- CittadinanzattivacoreCittadinanzattiva, with Roche's non-conditional contribution, promoted the 'Manifesto per il diritto alla medicina personalizzata' (Manifesto for the right to personalized medicine), defining 11 patient rights and 6 concrete actions to support them. Cittadinanzattiva also developed the 'Raccomandazione Civica' (Civic Recommendation), a roadmap of 9 commitments and 43 actions for personalized medicine implementation.
- Cergas - BocconiminorRoche cites a study by Cergas - Bocconi (Bocconi University's Center for Research on Health and Social Care Management) estimating the economic value of compassionate use programs (CUP), demonstrating cost savings of 9,800 to 18,700 EUR per patient annually.
Scale indicators11 records
Recent moves7 records
Expansion highlights5 records
Roche Italia competitors and assessment
Company assessmentDirect peers
- Novartis Italia: Italian subsidiary of Novartis, a global pharmaceutical peer with comparable oncology, ophthalmology, and cardiovascular portfolios. Directly competes with Roche Italia across multiple therapeutic areas in the Italian SSN framework.
- Sanofi Italia: Italian subsidiary of Sanofi, with overlapping portfolios in rare diseases, immunology, neurology, and vaccines. Comparable multinational pharma structure with SSN-channel go-to-market.
- AstraZeneca Italia: Italian subsidiary of AstraZeneca, with a strong and growing oncology and rare-disease portfolio directly competing with Roche's Italian business in SSN-listed therapies.
- MSD Italia (Merck & Co.): Italian affiliate of Merck & Co., a leading competitor in immuno-oncology (Keytruda) and a direct rival to Roche's oncology franchise in the Italian hospital and SSN channel.
- Pfizer Italia: Italian subsidiary of Pfizer, with overlapping oncology and rare-disease pipelines, similarly channeled through SSN reimbursement. A direct competitor in clinical trial placement and commercial access in Italy.
- DiaSorin: Italian-headquartered diagnostics company with a comparable specialty-diagnostics and immunoassay portfolio. Directly competes with Roche Diagnostics Italia in hospital and laboratory channels.
- Bristol-Myers Squibb Italia: Italian subsidiary of BMS, a direct competitor in oncology and hematology, with comparable hospital-channel specialty care model and SSN market access focus.
- AbbVie Italia: Italian affiliate of AbbVie, a direct peer in oncology and immunology with SSN reimbursement exposure. Comparable scale of clinical research investment and specialty-care commercial model in Italy.
Broad incumbents
- Abbott Italia: Italian affiliate of Abbott, a broader incumbent in diagnostics, medical devices, and diabetes care (FreeStyle Libre). A significant competitor to Roche Diagnostics and Roche Diabetes Care Italy.
- Siemens Healthineers Italia: Italian subsidiary of Siemens Healthineers, a broad incumbent in diagnostic imaging, laboratory diagnostics, and laboratory automation. A competitor to Roche Diagnostics in the hospital and reference-laboratory segment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Roche Italia social profiles
Digital presenceRoche Italia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Roche Italia leadership team
Management profileNumber of profiles
Profiles7 records
Roche Italia subsidiaries and ownership
Company hierarchySubsidiaries3 records
Roche Italia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Roche Italia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Roche Italia
What does Roche Italia do?
Roche Italia develops, manufactures, and commercializes pharmaceutical products across oncology, rare diseases, infectious diseases, neuroscience, and ophthalmology, alongside a comprehensive diagnostics portfolio (molecular diagnostics, clinical chemistry, immunochemistry, tissue diagnostics, point-of-care testing, next-generation sequencing, and laboratory automation), and diabetes care solutions including continuous glucose monitoring devices and digital health platforms. The offerings are sold primarily to hospitals, laboratories, and the Italian National Health Service, supported by companion diagnostics and digital platforms.
Is Roche Italia a public or private company?
Roche Italia is a private company. It is classified as corporate owned and is currently operating.
When was Roche Italia founded?
Roche Italia was founded in 1897. It employs 251 to 500 people.
Where is Roche Italia based?
Roche Italia is headquartered in Monza, Lombardy, Italy, in the Europe region.
How does Roche Italia make money?
Five revenue lines are on record. Pharmaceutical Products are the primary driver. The others are diagnostic Solutions and Products, diabetes Care Solutions, integrated Services and Value-Added Services and innovative Reimbursement Models.
Who are Roche Italia's main competitors?
Direct peers on record are Novartis Italia, Sanofi Italia, AstraZeneca Italia, MSD Italia (Merck & Co.), Pfizer Italia, DiaSorin, Bristol-Myers Squibb Italia and AbbVie Italia. Broad incumbents are Abbott Italia and Siemens Healthineers Italia.
Does Roche Italia have an API?
No public API is recorded for Roche Italia.
What industry is Roche Italia in?
Roche Italia's product category is Pharmaceuticals and Diagnostics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.